Robert W. Baird Believes Thermo Fisher (NYSE: TMO) Won’t Stop Here

In a report issued on July 28, Catherine Ramsey Schulte from Robert W. Baird maintained a Buy rating on Thermo Fisher (TMOResearch Report), with a price target of $555.00. The company’s shares closed last Friday at $540.01, close to its 52-week high of $543.30.

According to, Schulte is a top 100 analyst with an average return of 36.4% and a 79.9% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Twist Bioscience, and NanoString Tech.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Thermo Fisher with a $586.22 average price target, representing a 9.6% upside. In a report issued on July 16, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $580.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $543.30 and a one-year low of $401.07. Currently, Thermo Fisher has an average volume of 1.6M.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services segments. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.